A Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic Pancreatic Cancer

NCT06199466 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

4

Enrollment

OTHER

Sponsor class

Stopped \<75 % participation

Conditions

Metastatic Pancreatic Cancer

Interventions

DRUG: Gemcitabine
DRUG: Nab-paclitaxel
DRUG: YL-13027

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]